Restless Leg Syndrome Market Prepares To Move As GSK, UCB Advance Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS